Stopping rules for clinical trials

descriptionPublicationkeyboard_double_arrow_right Article 01 Apr 1983 English Publisher:WileyJournal:Statistics in Medicine, volume 2, pages 167-174 (issn: 0277-6715, eissn: 1097-0258,

Copyright policy )

Authors: L S, Freedman; D, Lowe; P, Macaskill;

doi: 10.1002/sim.4780020210

pmid: 6648131

Stopping rules for clinical trials

- Summary
- Subjects
- Metrics

Abstract

AbstractWe describe a new method of formulating stopping rules for clinical trials, one that incorporates opinion on what difference is clinically important. We compare the method with conventional group sequential designs and illustrate it by application to a study of Pancuronium Bromide for prevention of haemorrhage in pre‐term infants.

Related Organizations

MRC Laboratory of Molecular Biology
United Kingdom
MRC Biostatistics Unit
United Kingdom
Medical Research Council
United Kingdom

Keywords

Clinical Trials as Topic, Therapeutic Equivalency, Research Design, Statistics as Topic, Infant, Newborn, Humans, Pancuronium, Vitamin K Deficiency Bleeding

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	14
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average